Int J Thyroidol.  2020 Nov;13(2):72-78. 10.11106/ijt.2020.13.2.72.

Optimal Extent of Surgery for Papillary Thyroid Carcinoma

• Kim WW

• KMID: 2509183
• DOI: http://doi.org/10.11106/ijt.2020.13.2.72

Abstract

The goal of thyroid cancer surgery is the complete removal of the cancer, verification that patients receive appropriate treatment through accurate staging after surgery, minimization of local recurrence, and improvement of survival rate. However, maintaining the patient’s functional outcome and quality of life by minimizing postoperative complications as well as having good oncological outcomes is also important. To determine the optimal surgical extent, appropriate diagnosis and evaluation should be made on age, gender, tumor size, multiplicity, extrathyroidal extension, lymph node/distant metastasis, and biologic aggressiveness. In the low-risk group, lobectomy is required, and experienced high-volume surgeons may consider ipsilateral prophylactic central lymph node dissection because of the acceptable risk of hypoparathyroidism. In the intermediate-risk group, personalized decision-making should be determined according to the patient’s preferences and characteristics while also considering the pros and cons of lobectomy or total thyroidectomy. For the patient with high-risk factors, total thyroidectomy is considered. However, if a total thyroidectomy is not absolutely necessary and complications are expected, lobectomy could be a second option. If the patient has central lymph node metastasis, a therapeutic central lymph node dissection must be performed, and in the case of high-risk groups (T3/4 and N1b), ipsilateral prophylactic node dissection should be considered, and the contralateral parathyroid gland should be preserved. In the high-risk group (especially with massive ipsilateral lymph node metastasis or gross extrathyroidal involvement), the surgeon may consider bilateral central lymph node dissection if the ipsilateral parathyroid gland and the recurrent laryngeal nerve are well preserved, because of the risk of contralateral lymph node metastasis.

Keyword

Optimal extent; Papillary thyroid cancer; Surgery

Reference

References

1. Wharry LI, McCoy KL, Stang MT, Armstrong MJ, LeBeau SO, Tublin ME, et al. 2014; Thyroid nodules (>/=4 cm): can ultrasound and cytology reliably exclude cancer? World J Surg. 38(3):614–21. DOI: 10.1007/s00268-013-2261-9. PMID: 24081539.

2. Bongiovanni M, Spitale A, Faquin WC, Mazzucchelli L, Baloch ZW. 2012; The Bethesda System for Reporting Thyroid Cytopathology: a meta-analysis. Acta Cytol. 56(4):333–9. DOI: 10.1159/000339959. PMID: 22846422.

3. Na DG, Kim JH, Sung JY, Baek JH, Jung KC, Lee H, et al. 2012; Core-needle biopsy is more useful than repeat fine-needle aspiration in thyroid nodules read as nondiagnostic or atypia of undetermined significance by the Bethesda system for reporting thyroid cytopathology. Thyroid. 22(5):468–75. DOI: 10.1089/thy.2011.0185. PMID: 22304417.

4. Kim SK, Hwang TS, Yoo YB, Han HS, Kim DL, Song KH, et al. 2011; Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status. J Clin Endocrinol Metab. 96(3):658–64. DOI: 10.1210/jc.2010-1082. PMID: 21239517.

5. Ali SZ, Cibas ES. 2010. The Bethesda system for reporting thyroid cytopathology. Definitions, criteria and explanatory notes. Springer;New York: p. 1–166. DOI: 10.1007/978-0-387-87666-5.

6. Nikiforov YE, Ohori NP, Hodak SP, Carty SE, LeBeau SO, Ferris RL, et al. 2011; Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 96(11):3390–7. DOI: 10.1210/jc.2011-1469. PMID: 21880806. PMCID: PMC3205883.

7. Clain JB, Scherl S, Dos Reis L, Turk A, Wenig BM, Mehra S, et al. 2014; Extrathyroidal extension predicts extranodal extension in patients with positive lymph nodes: an important association that may affect clinical management. Thyroid. 24(6):951–7. DOI: 10.1089/thy.2013.0557. PMID: 24443878.

8. Wang Z, Chen JQ, Liu JL, Qin XG. 2016; Clinical impact of BRAF mutation on the diagnosis and prognosis of papillary thyroid carcinoma: a systematic review and meta-analysis. Eur J Clin Invest. 46(2):146–57. DOI: 10.1111/eci.12577. PMID: 26648183.

9. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, et al. 2013; Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 309(14):1493–501. DOI: 10.1001/jama.2013.3190. PMID: 23571588. PMCID: PMC3791140.

10. Moon S, Song YS, Kim YA, Lim JA, Cho SW, Moon JH, et al. 2017; Effects of coexistent BRAF(V600E) and TERT promoter mutations on poor clinical outcomes in papillary thyroid cancer: a meta-analysis. Thyroid. 27(5):651–60. DOI: 10.1089/thy.2016.0350. PMID: 28181854.

11. Mazzaferri EL. 2007; Management of low-risk differentiated thyroid cancer. Endocr Pract. 13(5):498–512. DOI: 10.4158/EP.13.5.498. PMID: 17872353.

12. Hay ID, Hutchinson ME, Gonzalez-Losada T, McIver B, Reinalda ME, Grant CS, et al. 2008; Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery. 144(6):980–7. discussion 7–8. DOI: 10.1016/j.surg.2008.08.035. PMID: 19041007.

13. Lee J, Park JH, Lee CR, Chung WY, Park CS. 2013; Long-term outcomes of total thyroidectomy versus thyroid lobectomy for papillary thyroid microcarcinoma: comparative analysis after propensity score matching. Thyroid. 23(11):1408–15. DOI: 10.1089/thy.2012.0463. PMID: 23509895.

14. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, et al. 2007; Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 246(3):375–81. discussion 81–4. DOI: 10.1097/SLA.0b013e31814697d9. PMID: 17717441. PMCID: PMC1959355.

15. Barney BM, Hitchcock YJ, Sharma P, Shrieve DC, Tward JD. 2011; Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. Head Neck. 33(5):645–9. DOI: 10.1002/hed.21504. PMID: 20687168.

16. Gartland RM, Lubitz CC. 2018; Impact of extent of surgery on tumor recurrence and survival for papillary thyroid cancer patients. Ann Surg Oncol. 25(9):2520–5. DOI: 10.1245/s10434-018-6550-2. PMID: 29855833. PMCID: PMC6070400.

17. Vargas-Pinto S, Romero Arenas MA. 2019; Lobectomy compared to total thyroidectomy for low-risk papillary thyroid cancer: a systematic review. J Surg Res. 242:244–51. DOI: 10.1016/j.jss.2019.04.036. PMID: 31103828.

18. Ryu J, Ryu YM, Jung YS, Kim SJ, Lee YJ, Lee EK, et al. 2013; Extent of thyroidectomy affects vocal and throat functions: a prospective observational study of lobectomy versus total thyroi-dectomy. Surgery. 154(3):611–20. DOI: 10.1016/j.surg.2013.03.011. PMID: 23932596.

19. Rosato L, Pacini F, Panier Suffat L, Mondini G, Ginardi A, Maggio M, et al. 2015; Post-thyroidectomy chronic asthenia: self-deception or disease? Endocrine. 48(2):615–20. DOI: 10.1007/s12020-014-0353-4. PMID: 25033997.

20. Scerrino G, Melfa G, Raspanti C, Attard A, Mazzola S, Gullo R, et al. 2017; The prevalence of post-thyroidectomy chronic asthenia: a prospective cohort study. Langenbecks Arch Surg. 402(7):1095–102. DOI: 10.1007/s00423-017-1568-7. PMID: 28299450.

21. Caliskan M, Park JH, Jeong JS, Lee CR, Park SK, Kang SW, et al. 2012; Role of prophylactic ipsilateral central compartment lymph node dissection in papillary thyroid microcarcinoma. Endocr J. 59(4):305–11. DOI: 10.1507/endocrj.EJ11-0366. PMID: 22240889.

22. Chen L, Wu YH, Lee CH, Chen HA, Loh EW, Tam KW. 2018; Prophylactic central neck dissection for papillary thyroid carcinoma with clinically uninvolved central neck lymph nodes: a systematic review and meta-analysis. World J Surg. 42(9):2846–57. DOI: 10.1007/s00268-018-4547-4. PMID: 29488066.

23. Wang TS, Cheung K, Farrokhyar F, Roman SA, Sosa JA. 2013; A meta-analysis of the effect of prophylactic central compartment neck dissection on locoregional recurrence rates in patients with papillary thyroid cancer. Ann Surg Oncol. 20(11):3477–83. DOI: 10.1245/s10434-013-3125-0. PMID: 23846784.

24. Raffaelli M, De Crea C, Sessa L, Giustacchini P, Revelli L, Bellantone C, et al. 2012; Prospective evaluation of total thyroidectomy versus ipsilateral versus bilateral central neck dissection in patients with clinically node-negative papillary thyroid carcinoma. Surgery. 152(6):957–64. DOI: 10.1016/j.surg.2012.08.053. PMID: 23158170.

25. Sadowski BM, Snyder SK, Lairmore TC. 2009; Routine bilateral central lymph node clearance for papillary thyroid cancer. Surgery. 146(4):696–703. discussion -5DOI: 10.1016/j.surg.2009.06.046. PMID: 19789029.

26. Kim WW, Park HY, Jung JH. 2013; Surgical extent of central lymph node dissection in clinically node-negative papillary thyroid cancer. Head Neck. 35(11):1616–20. DOI: 10.1002/hed.23197. PMID: 23322499.

27. Turanli S. 2007; Is the type of dissection in lateral neck metastasis for differentiated thyroid carcinoma important? Otolaryngol Head Neck Surg. 136(6):957–60. DOI: 10.1016/j.otohns.2006.12.013. PMID: 17547987.